Profile
ABVC VRTX ALNY REGN ARGX SGEN
Company Name ABVC BioPharma, Inc. Vertex Pharmaceuticals Incorporated Alnylam Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. argenx SE Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $46.66M $100.41B $59.77B $58.74B $48.87B $43.15B
Employees 0.02K 6.10K 2.23K 15.16K 1.60K 3.26K
CEO Uttam Yashwant Patil Reshma Kewalramani FASN, Yvonne L. Greenstreet Leonard S. Schleifer Timothy Van Hauwermeiren EMBA, David R. Epstein
Ratings
ABVC VRTX ALNY REGN ARGX SGEN
Quant Rating Score 1 3 1 4 3 3
Quant Rating Strong Sell Neutral Strong Sell Buy Neutral Neutral
Trading
ABVC VRTX ALNY REGN ARGX SGEN
Last Close $3.24 $421.15 $450.68 $563.86 $798.94 $228.74
High 52 $4.76 $516.74 $482.13 $1016.53 $800 $228.74
Low 52 $0.41 $366.54 $224.58 $482.92 $520.52 $228.74
Price vs. 52 Week High -31.93 % -18.5 % -6.52 % -44.53 % -0.13 % 0 %
Price vs. 52 Week Low 690.24 % 14.9 % 100.68 % 16.76 % 53.49 % 0 %
Total Return
ABVC VRTX ALNY REGN ARGX SGEN
1 Month Return 17.82 % 6.22 % -6.52 % 1.32 % 4.1 % 0 %
3 Month Return -30.77 % -12.07 % 40.53 % 2.06 % 43.9 % 0 %
6 Month Return 230.61 % -12.68 % 85.28 % -2.14 % 41.7 % 0 %
9 Month Return 506.74 % 2.19 % 87.35 % -23.14 % 23.05 % 0 %
YTD Return 449.15 % 4.58 % 91.53 % -20.84 % 29.91 % 0 %
1 Year Return 503.02 % -10 % 66.36 % -44.29 % 53.49 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ABVC VRTX ALNY REGN ARGX SGEN
Dividend Yield Percentage (TTM) - - - 0.47 % - -
Dividend Paid and Capex Coverage Ration (TTM) -7.5415073052426E+15 % 11.09 % -0.43 % 4.37 % 65.28 % -5.87 %
Dividend Per Share (TTM) - - - 2.64 % - -
Payout Ratio (TTM) - - - 4.18 % - -
Growth
ABVC VRTX ALNY REGN ARGX SGEN
Asset Growth -47.97 % -0.87 %
Gross Profit Growth 439.22 % 10.25 %
Revenue Growth 234.31 % 11.66 %
Revenue 3 Year -69.27 % 45.6 %
Revenue 5 Year -89.11 % 163.93 %
Revenue 10 Year 3545.91 % 1632.15 %
EBIT Growth 32.29 % -93.69 %
Net Income Growth 37.04 % -114.8 %
Net Income 3 Yeari Growth Per Share 91.81 % -122.89 %
Net Income 5 Yeari Growth Per Share 79.82 % -145.38 %
Net Income 10 Yeari Growth Per Share -3551.24 % 33.84 %
Operating Income Growth 30.47 % -106.08 %
Operating Cash Flow Growth (CFG) 57.29 % -113.93 %
Operating 3 Year CFG 94.89 % -118.65 %
Operating 5 Year CFG 91.35 % -131.3 %
Operating 10 Year CFG -13043.75 % 12.43 %
EPS Growth 76.67 % -114.8 %
EPS Diluted Growth 76.67 % -114.97 %
Book Value Per Share -96.69 % -6.59 %
Share Holder 3 Year Equity Growth Per Share -97.02 % 62.6 %
Share Holder 5 Year Equity Growth Per Share 221.75 % 168.85 %
Share Holder 10 Year Equity Growth Per Share 913.68 % 1292.6 %
Dividend Per Share Growth - -
Dividend 3 Year Growth Per Share - -
Dividend 5 Year Growth Per Share - -
Dividend 10 Year Growth Per Share - -
Debt Growth 40.26 % 116.42 %
Free Cash Flow Growth 57.5 % -124.1 %
Updated On 31 Dec 2024 31 Dec 2024
Profitability
ABVC VRTX ALNY REGN ARGX SGEN
Gross Profit Margin TTM 50.14 % 86.11 % 83.64 % 81.98 % 65.82 % 79.1 %
Return on Assets TTM -18.82 % 15.13 % -6.99 % 11.67 % 15.06 % -16.61 %
Return on Equity TTM -55.56 % 22.14 % -274.21 % 15.11 % 18.96 % -20.8 %
Return on Capital Employed TTM -33.7 % 19.72 % -5.52 % 11.45 % 5.04 % -21.46 %
Net Income Per EBT TTM 93.8 % 83.16 % 84.06 % 91.46 % 237.3 % 101.33 %
EBT Per Ebit TTM 99.58 % 111.48 % 210.66 % 123.23 % 147.38 % 98.26 %
EBIT Per Revenue TTM -836.32 % 34.36 % -7.32 % 27.83 % 13.47 % -31.24 %
Cash Flow To Debt Ratio TTM -110.75 % 251.83 % -1.2 % 175.35 % 932.29 % -1043.73 %
Receivables Turnover TTM 0.28 6.03 4.34 2.53 1.91 3.91
Payables Turnover TTM - 3.59 3.93 3.54 0.9 1.97
Inventory Turnover TTM 17.2 1.06 5.62 0.8 2.26 0.96
Fixed Asset Turnover TTM 4.51 % 431.08 % 355.68 % 293.64 % 5009.77 % 665.41 %
Asset Turnover TTM 2.41 % 47.51 % 53.92 % 37.19 % 31.97 % 53.41 %
Operating Cash Flow Per Share TTM -0.1 14.98 -0.12 45.13 5.67 -2.46
Free Cash Flow Per Share TTM -0.1 13.63 -0.4 36.58 5.58 -2.88
Cash Per Share TTM 2.61 % 2486.48 % 2203.63 % 7107.14 % 5536.58 % 939.52 %
Operating Cash Flow Sales Ratio TTM -448.8 % 33.68 % -0.63 % 33.37 % 17.54 % -23.12 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 90.99 % 335.21 % 81.05 % 98.47 % 117.04 %
Cash Flow Coverage Ratios TTM -110.75 % 251.83 % -1.2 % 175.35 % 932.29 % -1043.73 %
Price To Free Cash Flows Ratio TTM -26.57 28.69 -1147.52 15.28 122.57 -81.26
Price To Operating Cash Flows Ratio TTM -31.88 26.14 -3805.41 12.49 140 -93.1
Price Cash Flow Ratio TTM -31.88 26.14 -3805.41 12.49 140 -93.1
Income Statement (TTM)
ABVC VRTX ALNY REGN ARGX SGEN
Revenue $0B $11.02B $2.25B $14.2B $2.19B $1.96B
Gross Profit $0B $9.49B $1.92B $11.75B $1.96B $1.55B
Gross Profit Ratio 99.85% 86.11% 85.62% 82.74% 89.62% 79.1%
EBITDA $-0B $0.49B $-0.18B $5.32B $0.11B $-0.62B
Net Income $-0B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
EPS Diluted -0.42 -2.08 -2.16 38.34 12.78 -3.3
Balance Sheet (MRQ)
ABVC VRTX ALNY REGN ARGX SGEN
Long Term Debt $0B $1.66B $1.25B $2.7B $0.03B $0.04B
Total Liabilities $0.01B $6.12B $4.17B $8.41B $0.7B $0.87B
Total Equity $0B $16.41B $0.07B $29.35B $5.5B $2.8B
Total Investments $0B $6.65B $1.73B $15.42B $1.93B $1.42B
Total Debt $0B $1.75B $1.3B $2.7B $0.04B $0.04B
Total Assets $0.01B $22.53B $4.24B $37.76B $6.2B $3.67B
Cash Flow Statement (TTM)
ABVC VRTX ALNY REGN ARGX SGEN
Net Income $-0.01B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
Inventory $0B $-0.52B $0.01B $-0.62B $-0.1B $-0.23B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0B $-0.49B $-0.01B $4.42B $-0.08B $-0.45B
Capital Expenditure $0B $-0.3B $-0.03B $-0.76B $-0.07B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 40.23
AARD Aardvark Therapeutics, Inc. Common Stock 17.13
ABCL AbCellera Biologics Inc. 6.17
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.54
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.88
ABPWW 0.0255
ABSI Absci Corporation 4.18
ABUS Arbutus Biopharma Corporation 4.18
ABVX Abivax SA American Depositary Shares 86.51
ACAD ACADIA Pharmaceuticals Inc. 21.31
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.9287
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 3.45
ACIU AC Immune SA 3.52
ACLX Arcellx, Inc. 88.29
ETFs With Exposure to ABVC
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 331.81
VXF Vanguard Extended Market Index Fund 0.00051 212.75
IWC iShares Micro-Cap ETF 0 154.2
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0.00051 161.41
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0.00051 161.42
VEMPX Vanguard Extended Market Index InstlPlus 0.00051 398.32
Unlock